Recent Finacing
Recent Raise
AltruBio is a clinical-stage biotechnology company developing PSGL-1 immune checkpoint agonist antibodies (neihulizumab/ALTB-168 and tetravalent ALTB-268) to downregulate chronically activated T cells for autoimmune and inflammatory diseases.
